News & Updates

Show Multimedia Only

Poststroke chronic vertigo and dizziness require individualized rehabilitation

03 Jan 2026 by

The significantly poorer health-related quality of life (HRQoL) in patients with chronic vertigo and dizziness compared with those without, following a stroke, necessitates systematic poststroke screening, comprehensive multidisciplinary assessment and individualized rehabilitation, according to a stroke cohort study.

Poststroke chronic vertigo and dizziness require individualized rehabilitation

03 Jan 2026

Childhood maltreatment increases schizophrenia risk 5-fold

02 Jan 2026 by

Childhood maltreatment increases the risk of schizophrenia by five-fold, attention deficit hyperactivity disorder (ADHD) by 10-fold, and major depressive disorder (MDD) by nearly two-fold. It also leaves lasting genetic markers linked to neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease, a Mendelian randomization study has shown.

Childhood maltreatment increases schizophrenia risk 5-fold

02 Jan 2026

Lubiprostone use heightens risk of headache

30 Dec 2025

Treatment with lubiprostone is associated with an increased risk of headache in adults and children, according to a recent meta-analysis.

Lubiprostone use heightens risk of headache

30 Dec 2025

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

30 Dec 2025 by

Migraine is a highly disabling neurological condition that profoundly affects patients’ quality of life (QoL) and productivity. Traditional first-line (1L) preventive treatments were not originally developed for migraine and are often limited by suboptimal efficacy and poor tolerability. In an interview with MIMS Doctor, Dr William Kingston of the Division of Neurology, Department of Medicine, Temerty School of Medicine, University of Toronto, Canada, discussed the emergence of calcitonin gene–related peptide (CGRP) inhibitors, including atogepant, as a significant breakthrough in migraine prevention, offering targeted, migraine[1]specific efficacy with improved tolerability.

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

30 Dec 2025

Impaired kidney function influences AD blood biomarkers but not dementia risk

17 Dec 2025 by

Among individuals without cognitive impairment, those with impaired kidney function exhibit increased levels of Alzheimer’s disease (AD) blood biomarkers, although they do not appear to be at increased risk of dementia compared with those who have preserved kidney function, according to new research.

Impaired kidney function influences AD blood biomarkers but not dementia risk

17 Dec 2025

EPVS burden a potential marker of CSVD, AD-related pathology

17 Dec 2025 by

A study from Singapore reports the potential of enlarged perivascular space (EPVS) burden as a marker of cerebral small vessel disease (CSVD) and Alzheimer’s disease (AD)-related blood-based biomarker (BBM) pathology.

EPVS burden a potential marker of CSVD, AD-related pathology

17 Dec 2025

Arterial stiffness linked to small-, large-fiber neuropathy

15 Dec 2025 by

A recent study has shown the association of greater arterial stiffening with both ocular (small) and peripheral (large) fiber neuropathies.

Arterial stiffness linked to small-, large-fiber neuropathy

15 Dec 2025

Sleep apnoea may pose increased Parkinson’s disease risk

11 Dec 2025 by

People with obstructive sleep apnoea seem predisposed to later development of Parkinson’s disease, but this risk can be mitigated by early treatment with continuous positive airway pressure, as reported in a study.

Sleep apnoea may pose increased Parkinson’s disease risk

11 Dec 2025

Epilepsy risk elevated in children with congenital Zika syndrome

10 Dec 2025 by

New research suggests that in-utero exposure to Zika virus (ZIKV) alone does not increase the risk of epilepsy in early childhood, and the risk increase is limited to children who develop congenital Zika syndrome.

Epilepsy risk elevated in children with congenital Zika syndrome

10 Dec 2025

Plasma p-tau217 detects Alzheimer's disease in preclinical stage

09 Dec 2025 by

Plasma phosphorylated tau 217 (p-tau217) can identify pathological changes characteristic of Alzheimer’s disease (AD) in older adults without cognitive impairment, according to a meta-analysis.

Plasma p-tau217 detects Alzheimer's disease in preclinical stage

09 Dec 2025

News & Updates

Showing Neurology articles

Showing

Specialty:

Poststroke chronic vertigo and dizziness require individualized rehabilitation

Poststroke chronic vertigo and dizziness require individualized rehabilitation

Childhood maltreatment increases schizophrenia risk 5-fold

Childhood maltreatment increases schizophrenia risk 5-fold

Lubiprostone use heightens risk of headache

Lubiprostone use heightens risk of headache

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

Impaired kidney function influences AD blood biomarkers but not dementia risk

Impaired kidney function influences AD blood biomarkers but not dementia risk

EPVS burden a potential marker of CSVD, AD-related pathology

EPVS burden a potential marker of CSVD, AD-related pathology

Arterial stiffness linked to small-, large-fiber neuropathy

Arterial stiffness linked to small-, large-fiber neuropathy

Sleep apnoea may pose increased Parkinson’s disease risk

Sleep apnoea may pose increased Parkinson’s disease risk

Epilepsy risk elevated in children with congenital Zika syndrome

Epilepsy risk elevated in children with congenital Zika syndrome

Plasma p-tau217 detects Alzheimer's disease in preclinical stage

Plasma p-tau217 detects Alzheimer's disease in preclinical stage